ResMed Grows Core Revenue 7% in First Quarter

The medical device maker reported the growth on its October 29, 2026 earnings call after selling its MatrixCare software business.

Updated on Nov. 2, 2026 in Healthcare

Bold vector editorial illustration of smooth rounded mask cushions and coiled tubing beside stacked components, in coral, teal, and cream. — ResMed reported 7% core revenue growth for its fiscal first quarter on October 29, 2026, and returned more than $1 billion to shareholders after selling its MatrixCare software business. AI Illustration. Upload story photo >

ResMed reported 7% core revenue growth on its first quarter of fiscal year 2027 earnings call held October 29, 2026. The company said it returned more than $1 billion to shareholders in the quarter, a record for ResMed, funded in part by proceeds from the sale of its MatrixCare software business.

Why it matters

The divestiture lets ResMed concentrate resources on its core medical devices and digital health software. The results also reflect margin gains from supply chain and manufacturing improvements despite inflation pressure on electronic components.

ResMed posted 7% core revenue growth and roughly 50 basis points of gross margin expansion in the quarter, with more than $1 billion returned to shareholders. The filing does not break out how much of that capital return came from MatrixCare sale proceeds versus operating cash.

The players

ResMed

ResMed is a medical device company known for sleep apnea and respiratory care equipment, including CPAP therapy systems.

The details

ResMed sold MatrixCare, its noncore long-term care software business, and used the proceeds to fund share repurchases. The company also cited data showing patients with prescriptions for both CPAP and GLP-1 medications are more than 11% more likely to start CPAP therapy than those with a CPAP prescription alone.

October 29, 2026: ResMed holds its first quarter of fiscal year 2027 earnings call.
Over the next three years: GLP-1 patients are expected to purchase replacement masks more consistently.
2030: Target year for ResMed's 2030 strategy and 5-year outlook.

Industry Landscape

ResMed's data on GLP-1 patients extends the growing connection between weight-loss drug prescriptions and sleep apnea treatment, a link that has drawn attention across the medical device sector. The company's projection of high single-digit top-line growth over five years shows it is positioning for that expanding diagnostic demand.

Patients who use CPAP therapy may see more consistent replacement mask supply as GLP-1 patients enter treatment over the coming years. The data suggests that patients prescribed GLP-1 medications may also be more likely to start CPAP therapy.

The takeaway

Patients who are starting GLP-1 treatment should ask their clinicians whether a sleep apnea evaluation is appropriate, since the data links those prescriptions to higher CPAP start rates.